Applied Genetic Technologies

Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Washington D.C--(Newsfile Corp. - August 4, 2020) - At today’s meeting of the Small Business Capital Formation Advisory Committee, the Securities and Exchange Commission announced the appointment of two new members to the Committee:Kesha Cash, Founder and General Partner, Impact America FundSue Washer, President and CEO, Applied Genetic Technologies Corporation (NASDAQ: AGTC)The new members were appointed following the resignations of Terry McNew, former President and.

SEC Announces New Small Business Capital Formation Advisory Committee Members

FDA feedback allows for forward program development

AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial

Does Applied Genetic Technologies (AGTC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Applied Genetic Technologies (AGTC) is a Great Momentum Stock to Buy

Is  (AGTC) Outperforming Other Medical Stocks This Year?

Is Applied Genetic Technologies (AGTC) Stock Outpacing Its Medical Peers This Year?

Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Applied Genetic (AGTC) Soars: Stock Adds 6.1% in Session

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June  24, 2020  (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, according to a preliminary list of additions posted on June 5.

AGTC Set to Join Russell 3000® and 2000® Indexes

Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials

AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June  16, 2020  (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 at 10:30 am ET.

AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020

Mobile vision testing unit enables X-linked retinitis pigmentosa and achromatopsia clinical trial patients to maintain important scheduled study assessments during COVID-19 pandemic

AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials

Phunware Inc

SeaWorld Entertainment

Six Flags

Tapestry

If you’re looking to hedge your portfolio to protect some downside, or make some bets against high valuations, our deep learning algorithms have paired with our Artificial Intelligence (“AI”) technology to produce some Top Shorts today.

Top Companies To Short As Nasdaq Surges To Record-Breaking Heights

The Applied Genetic Technologies (AGTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Applied Genetic Technologies (AGTC) Stock Might be a Great Pick

Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Applied Genetic Technologies (AGTC) Upgraded to Strong Buy: Here's What You Should Know

Is Applied Genetic Technologies (AGTC) Outperforming Other Medical Stocks This Year?

Applied Genetic Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

 -  Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile -

AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q3 2020 Results - Earnings Call Transcript

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 9.09% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Applied Genetic Technologies (AGTC) Reports Q3 Loss, Misses Revenue Estimates

As of late, it has definitely been a great time to be an investor in Applied Genetic Technologies.

Applied Genetic Technologies' Shares March Higher, Can It Continue?

Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Applied Genetic Technologies (AGTC) Q3 Earnings Expected to Decline

Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Applied Genetic Technologies (AGTC) Rating Upgrade to Buy

Enrollment ongoing in pediatric dose groups

AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb.  19, 2020  (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed enrollment in the two highest dose groups of its Phase 1/2 clinical trial evaluating the safety and efficacy of sub-retinal injection of AGTC-501 for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. The patients in these additional groups received a higher or highest dose of AGTC’s XLRP candidate.

AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb.  06, 2020  (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $5.00 per share, less underwriting discounts and commissions. In addition, AGTC has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common stock at the public offering price per share, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to be $32,500,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by AGTC. All of the shares are being sold by AGTC. The offering is expected to close on or about February 11, 2020, subject to satisfaction of customary closing conditions.

AGTC Announces Pricing of $32,500,000 Public Offering of Common Stock

In the last year, sell-side analysts have shown confidence in Applied Genetic Technologies Corp (NASDAQ: AGTC) with a series of upgrades and initiations.

Exclusive: Applied Genetic's CEO Talks Partnerships, Politics, Pipeline

Shares of Applied Genetic Technologies Corp (NASDAQ: AGTC) are tumbling Thursday despite the company reporting encouraging results from an Phase 1/2 study.

News for Applied Genetic Technologies Stock (AGTC)